Frequently Asked Questions: SARS-CoV-2 Testing
Recently, PDI announced promising testing results of Super Sani-Cloth® Wipes against SARS-CoV-2, the virus that causes COVID-19. Below are some Frequently Asked Questions that address this new information:
Q. Has PDI received claim approval for Super Sani-Cloth® Wipes against SARS-CoV-2?
A. At this time, PDI has submitted its SARS-CoV-2 testing data to the EPA and is awaiting approval.
According to the data, the wipes demonstrated a 3-log reduction against the virus. The wipes were tested in compliance with “Disinfectants for Use on Environmental Surfaces, Guidance for Efficacy Testing,” the EPA’s threshold for deeming a disinfectant effective.
Q. Is PDI testing any other products for efficacy against SARS-CoV-2?
A. Yes, Sani-Cloth® Bleach Wipes, Sani-Cloth® AF3 Wipes, Sani-Cloth® Prime Wipes, Sani-Prime® Spray and Sani-HyPerCide® Spray (included on EPA’s List N entitled “Disinfectants for Use Against SARS-CoV-2”) are currently being tested by Microbac with results expected in the coming months.
Q. When does PDI expect EPA’s response on SARS-CoV-2 data submitted for Super Sani-Cloth® Wipes?
A. EPA review of new efficacy data for an existing product to support new public health label claims, such as SARS-CoV-2, is typically 4 months. EPA is working hard to expedite these reviews and shorten the review time in light of the pandemic.
Q. How was efficacy testing performed at Microbac to obtain SARS-CoV-2 data for Super Sani-Cloth® Wipes?
A. Microbac performed the efficacy testing using a multi-step process. First, the lab applied the virus to a surface and let it dry. Then, they wiped the surface with a Super Sani-Cloth® wipe, recovered the residual liquid, and applied the liquid to cells in culture. How viable the cells remained told Microbac how effective the cloth was in inactivating the virus.
Q. How is the new SARS-CoV-2 claim different than being included on EPA’s List N?
A. Because SARS-CoV-2 is a new virus, this pathogen was not readily available at first for testing in a commercial laboratory to demonstrate efficacy.
In the interim, CDC recommended use of surface disinfectant products on EPA’s List N entitled “Disinfectants for Use Against SARS-CoV-2”.
While most surface disinfectant products on List N have not been tested specifically against SARS-CoV-2, the virus that causes COVID-19, EPA expects the List N products to kill the SARS-CoV-2 virus because they demonstrate efficacy (i.e. effectiveness) against a harder-to-kill virus; or against another type of human coronavirus similar to SARS-CoV-2.
PDI initiated testing as soon as the virus was available and has submitted data to the EPA demonstrating its Super Sani-Cloth® wipes, the number one disinfecting wipes in healthcare, are effective against SARS-CoV-2, the virus that causes COVID-19. This is one of several of the company’s hospital-grade disinfecting products being tested for efficacy against SARS-CoV-2 for submission to the EPA for approval. Testing of the additional disinfecting products is still underway, and results are expected in the upcoming months.